Allantoin.

Allantoin loosens the bonds between corneocytes at the surface while panthenol converts to pantothenic acid and holds water in the stratum corneum. They appear together in barrier creams because one smooths and the other hydrates.

Hyaluronic acid binds water at the surface while allantoin softens keratin and eases desquamation, so the retained water reaches a less compacted layer. This is standard practice in soothing formulas.

Aloe polysaccharides form a hydrating film and allantoin, which aloe itself contains in small amounts, softens the keratin layer beneath it. The combination is one of the oldest in topical soothing products.

Glycolic acid loosens corneocyte adhesion through the acid route and can leave the surface reactive. Allantoin is added as the keratin-softening agent that keeps the same formula comfortable.

Salicylic acid is lipophilic and works inside the follicle, while allantoin softens surface keratin and calms the reaction to it. Formulators pair them so the exfoliating step is better tolerated.

Niacinamide raises ceramide and free fatty acid production in the barrier layer while allantoin conditions the keratin already there. They cover synthesis and surface condition in the same product.

Ceramides refill the lipid matrix between corneocytes and allantoin eases the shedding of the cells that matrix holds together. The pairing addresses both the lipid and the protein side of the surface layer.

Squalane forms a light occlusive film that slows water loss, which keeps the keratin allantoin acts on hydrated enough to soften. It is a common carrier choice in allantoin creams.

Glycerin draws water into the upper skin layers and holds it there. Allantoin adds a keratin-softening action that glycerin does not have, so the two cover different parts of the same job. Allantoin has limited water solubility and can recrystallise, and the polyol phase of a formula helps keep it in solution.

Tocopherol protects the oil phase of a cream from oxidation and contributes to the conditioning feel. Allantoin sits in the water phase and does neither. This is a phase-complementary pairing common across topical products.

In human plasma, allantoin is formed largely by non-enzymatic oxidation of urate by reactive oxygen species, since humans lack a functioning uricase. Ascorbate competes for those same oxidants, so antioxidant status influences how much urate is oxidised. In topical products ascorbic acid is also acidic and can be harsh on reactive skin, which is why allantoin is often formulated alongside it. Allantoin in this setting is a marker of oxidation, not an outcome.

Retinol conversion in the skin is often accompanied by dryness and flaking during the first weeks of use. Allantoin softens keratin and holds water in the upper layers, which is why formulators put it in the same product. It does not change how retinol is converted or how much penetrates.

Xanthine oxidoreductase carries a molybdopterin cofactor and converts hypoxanthine to xanthine and xanthine to urate. Urate is then oxidised to allantoin, non-enzymatically in humans and enzymatically by uricase in most other mammals. This is a settled cofactor relationship in purine handling and explains why allantoin, hypoxanthine and xanthine appear together in metabolite panels.